During the past decade, Royal Free Hospital; Department of Rheumatology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Royal Free Hospital; Department of Rheumatology" are "Systemic Sclerosis" (3 trials), "Pulmonary Hypertension" (2 trials), "Rheumatoid Arthritis" (1 trials), "Scleroderma" (1 trials) and "Systemic Lupus Erythematosus" (1 trials). Many other conditions were trialed in "Royal Free Hospital; Department of Rheumatology" in a lesser frequency.

Most popular intervention types in "Royal Free Hospital; Department of Rheumatology" are "Drug" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Tocilizumab" (2 trials), "treprostinil diethanolamine" (2 trials), "Acetaminophen/Paracetamol" (1 trials) and "Bosentan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Royal Free Hospital; Department of Rheumatology" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Royal Free Hospital; Department of Rheumatology". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Royal Free Hospital; Department of Rheumatology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Royal Free Hospital; Department of Rheumatology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".